HoneyNaps Co., Ltd. is a digital healthcare and HealthTech company headquartered at 4F, Marin Building, 529 Nonhyeon-ro, Gangnam-gu, Seoul, South Korea (06126), with a US subsidiary, HoneyNaps USA Inc., based at One Broadway, Cambridge, Massachusetts, and an R&D partnership based at Yonsei University, Seoul. The company was founded in 2015 with an initial focus on developing the underlying technology for bio-signal monitoring, subsequently expanding into a full platform offering covering real-time data acquisition, AI-driven analysis, and clinical decision support for sleep disorders and related conditions.

HoneyNaps’ central platform technology, SOMNUM, is designed to enable medical professionals and researchers to access and apply bio-signal data across the full lifecycle of sleep monitoring — from raw signal acquisition through to disease prediction and therapeutic guidance. The company’s stated strategic framework is oriented around 4P Medicine — Prevention, Prediction, Participation, and Personalisation — positioning its technology as a tool for proactive, continuous health management rather than episodic clinical intervention.

The company’s sleep diagnosis algorithm holds FDA clearance, a regulatory milestone that provides a basis for commercialisation in the US market and lends credibility to the platform’s clinical validity. HoneyNaps has also been pursuing CE marking and KFDA (Korean Ministry of Food and Drug Safety) certification for its HoneyCube hardware product, and its software architecture is designed to be interoperable with established medical information standards including HL7, DICOM, and ISO interfaces, enabling integration with broader hospital and clinical information systems.

Key Products and Services

SOMNUM Platform

• Full-cycle bio-signal management and disease prediction platform designed for use by medical professionals and clinical researchers
• Integrates real-time bio-signal acquisition, data management, AI-based analysis, and therapeutic care guidance within a unified digital health architecture
• Designed with HL7, DICOM, and ISO interface compatibility to support integration with existing electronic health record and hospital information systems

HoneyCube — Sleep Bio-signal Monitoring Device

• Wearable or bedside bio-signal monitoring hardware capturing body temperature, heart rate, respiratory rate, and movement during sleep
• Continuous 24-hour data acquisition for sleep stage analysis, abnormal symptom detection, and longitudinal health monitoring
• CE marking and KFDA certification in progress; designed to interface directly with the SOMNUM platform for clinical data management

AI Sleep Data Diagnosis Algorithm

• FDA-cleared artificial intelligence algorithm for the automated analysis and diagnosis of sleep data
• Applies machine learning and deep learning methods to bio-signal data collected during sleep to generate clinically actionable diagnostic outputs
• Supports sleep disorder identification and monitoring, with applicability to conditions including obstructive sleep apnoea, insomnia, and other sleep-related pathologies

Disease Prediction Algorithm

• Predictive algorithm applying bio-signal and clinical data to forecast disease risk, enabling preventive intervention, personalised dietary and lifestyle guidance, insurance risk stratification, and elimination of downstream social and health risks
• Designed to extend the utility of collected bio-signal data beyond sleep diagnosis into broader chronic disease monitoring and early warning

Expert System for Medical Diagnosis

• Clinical decision support system designed to transfer precision diagnostic capability to point-of-care environments, including paediatric and family health contexts
• Positioned as a tool enabling personalised, lifelong health monitoring from early life onwards

HoneyNaps occupies a focused niche within the digital health and medical device landscape as a sleep-specialist bio-signal technology company with an FDA-cleared AI diagnostic algorithm — a regulatory credential that distinguishes it from the large number of consumer-grade sleep tracking products that do not hold clinical device clearance. Its combination of hardware (HoneyCube), platform software (SOMNUM), and AI-driven diagnostic and predictive algorithms positions it as a vertically integrated digital health company rather than a point-solution provider, with potential applicability across clinical sleep medicine, remote patient monitoring, and disease prevention programmes. The Cambridge, Massachusetts US office and the Yonsei University R&D partnership reflect an intent to build credibility and commercial presence in both the US and Korean markets simultaneously. As a relatively early-stage company with limited publicly disclosed commercial metrics, HoneyNaps’ primary differentiation rests on its FDA clearance and the technical depth of its AI platform rather than on established scale or client portfolio.